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Advances in genomic technology have produced an explosion of new information about the genetic
basis for human disease, fueling extraordinarily high expectations for improved treatments. This
perspective will take brief stock of what genetics/genomics have brought to clinical practice to
date and what we might expect for the future.Improved Diagnosis for Mendelian
Genetic Disorders
First the ‘‘good news’’: the contribution of
modern genetics and genomics to the
diagnosis of Mendelian genetic disorders
has been nothing short of spectacular.
The number of human single-gene disor-
ders with a known molecular genetic
cause has risen from less than 5 in
1982, to approximately 150 in 1990, and
to nearly 3,000 in 2011 (http://omim.org).
Precise DNA diagnosis in approved
clinical testing laboratories is available
for many of these disorders, and testing
on a research basis can be obtained
for a significant subset of the remaining
diseases. Although ambiguity still re-
mains for some sequence findings (e.g.,
‘‘variants of unknown significance’’),
definitive diagnosis can often be estab-
lished by DNA testing, and once a familial
mutation is known, testing of nearly
perfect sensitivity and specificity is
then available for other at-risk family
members, including prenatal and preim-
plantation diagnoses. These advances
have led to the near elimination of select
autosomal-recessive diseases in specific
populations, such as b-thalassemia in
parts of the Mediterranean and Tay-
Sachs disease among Ashkenazi Jews
(Zlotogora, 2009). Though the full power
of genetic diagnosis has not yet been fully
realized, major progress is clear, and the
impact of DNA testing on single-gene
disorders, particularly with the advent
of next-generation sequencing, is likely
to expand dramatically over the next
decade.Treatment for Mendelian Genetic
Disorders
Now for the ‘‘bad news’’: in contrast to the
remarkable impact on diagnosis, the
contribution of modern genetics and ge-
nomics to the treatment of most Mende-
lian genetic disorders has been, with
a few notable exceptions, a disappointing
failure. Among the 3,000 single-gene
disorders for which the responsible gene
has been identified, only a handful (<1%)
have been translated directly into new
therapies. Most of this success has been
restricted to diseases due to enzyme
deficiencies, such as hemophilia and the
lysozomal storage diseases. However,
for most genetic diseases, little has
changed in treatment since the discovery
of the responsible gene. Where modest
improvement in therapy has been seen,
this has generally been empiric and not
the direct result of knowing the underly-
ing genetic defect. Examples include
muscular dystrophy, whose gene was
identified in 1986, cystic fibrosis (1989),
and Huntington disease (1993). Sickle
cell anemia provides a particularly
humbling example for the biomedical
research community. Its molecular basis
has been understood at the 5.5 A˚ level
since 1960 (Perutz et al., 1960). However,
current therapy is still largely empiric
and not derived from a sophisticated
understanding of hemoglobin structure
and sickle cell anemia molecular patho-
genesis.
Chronic myelogenous leukemia (CML)
offers a striking exception for which
understanding genetic pathogenesis hasCell 147, Sindeed had a striking impact on treat-
ment. Imatinib (Gleevec), a targeted ther-
apeutic against the unique fusion gene
product (BCR/ABL) found in all CML
patients, has profoundly altered the prog-
nosis for patients with this disease.
Despite the initial enthusiasm that
designer drugs of this type would soon
become a routine follow-on to the
discovery of any pathogenic gene, few
such therapies with an impact of this
magnitude have yet emerged. It has
become increasingly clear that the path
for translation of basic genetic findings
into new therapeutics is not an easy one.
Although 3,000 Mendelian diseases
can now be diagnosed by DNA testing,
is this always of direct clinical value to
the patient? Medical test ordering by
physicians often follows a logic similar to
Mallory’s decision to climb Mount Ever-
est, simply ‘‘because it’s there.’’ This
approach has made unrestrained diag-
nostic testing a key contributor to
runaway health care costs. A transition
toward evidence-based medicine will
increasingly demand that diagnostic
tests, including DNA testing, be restricted
to those settings wherein a significant
impact on treatment and medical
management is anticipated. It is here
that our disappointing success rate in
translating genetic discovery into im-
proved medical treatment dampens the
significance of our triumph in the diag-
nostic arena. Unfortunately, a significant
fraction of DNA diagnostic tests currently
performed does not meet this standard
of evidence-based medical justification.eptember 30, 2011 ª2011 Elsevier Inc. 17
For example, one of the most commonly
performed genetic diagnostic tests in the
US today is for factor V Leiden, a common
human polymorphism that predisposes to
venous thrombosis. However, the results
of this test are of limited or no value in
guiding current medical therapy (Middel-
dorp, 2011).
Though modern genetics and geno-
mics have had a transforming impact on
our understanding of Mendelian human
genetic disorders, direct translation to
improved treatment remains elusive for
most patients. This relative failure to
date should not be a cause for resignation
or despair, but rather a call to redouble
our efforts. The path from basic discovery
to effective therapy is usually a long and
arduous one, and generally unpredict-
able. Recent history simply demonstrates
that identifying something as broken is
much easier than fixing it.
Complex Genetic Disorders
Single-gene disorders are estimated to
account for approximately 9% of child-
hood mortality and probably less than
2% of overall hospital admissions in the
US (Korf et al., 2007). The vast majority
of health care costs are devoted to the
treatment of common complex disorders
such as coronary artery disease, stroke,
diabetes, hypertension, and cancer,
which all appear to have large, heritable
components. The ‘‘common disease/
common variant’’ hypothesis has been
tested by genome-wide association
studies (GWAS) for over 220 diseases or
traits (Hindorff et al., 2011). Over 1,300
highly significant genetic risk loci have
been identified, though nearly all with
very modest effect (allelic odds ratios
generally < 1.5) and in aggregate ac-
counting for only a small fraction of the
overall genetic risk (Manolio et al., 2009).
Is information from GWAS clinically
useful in guiding medical management
or choice of therapy? At present, the clear
consensus among clinical genetic experts
is a resounding ‘‘no.’’ One prime example
is type 2 diabetes, where extensive
single-nucleotide polymorphism (SNP)
testing adds little to the much greater
predictive value of family history and
body mass index (Lyssenko et al., 2008).
The lack of demonstrated diagnostic or
therapeutic utility has not dissuaded the
enthusiastic direct-to-consumer (DTC)18 Cell 147, September 30, 2011 ª2011 Elsemarketing of whole-genome SNP analysis
for self-diagnosis of risk for a broad array
of diseases and common human traits.
Though the technical validity of SNP
calling seems high, risk prediction from
similar data varies dramatically between
different DTC companies, often in oppo-
site directions (Ng et al., 2009). The poten-
tial negative impact of DTC genetic
testing on medical practice and health
care cost containment has led to calls
for increased regulation and oversight.
Despite limited direct clinical payoff to
date, GWAS have nonetheless provided
important advances in our understanding
of several complex genetic diseases.
Examples include entirely unanticipated
insight into the role of complement factor
genes in the pathogenesis of age-related
macular degeneration (de Jong, 2006)
and the discovery of the BCL11A gene
as a critical regulator of fetal hemoglobin
levels and the long-sought-after basis for
the fetal to adult globin switch (Sankaran
et al., 2009). In addition, the observation
that common SNPs in aggregate gener-
ally account for <10%–20% of overall
genetic risk for most complex diseases
has sparked new efforts to identify the
genetic basis for the remaining ‘‘missing’’
heritability (Manolio et al., 2009).
Pharmacogenomics
There has been considerable enthusiasm
that the identification of common human
genetic variants would accurately predict
drug response and toxicity, allowing
precise tailoring of individualized or
‘‘personalized’’ treatments for patients
based on their specific disease and
genetic makeup. Nonetheless, progress
in this area remains limited and has not
yet proven as straightforward as initially
thought. Although there are several
clear-cut associations of specific genetic
variants with drug toxicity, genetic
screening prior to treatment has not yet
become a standard part of medical care.
As in disease diagnostics, pharmacoge-
nomic testing has often been greeted
with naive enthusiasm and advocated
well in advance of solid evidence for clin-
ical utility. A case in point is CYP2/C9 and
VKORC1 genotyping to predict response
to warfarin, a widely used oral anticoagu-
lant for which precise dosing is critical
(too low a dose leads to inadequate effi-
cacy as an anticoagulant and too highvier Inc.a dose to excessive bleeding). Common
variants in these two genes account for
30% of the variability in the individual
response to warfarin, leading the U.S.
Food and Drug Administration to modify
warfarin labeling to suggest CYP2/C9
and VKORC1 genotyping. However, this
testing has not yet been demonstrated
to be of practical clinical value in
decreasing bleeding complications or
increasing anticoagulant efficacy and is
rarely used in clinical practice (Rosove
and Grody, 2009).
Where Do We Go from Here?
The impact of next-generation sequencing
on human genetics, both diagnostically
and therapeutically, is likely to be transfor-
mational. With decreased cost and
improved quality over the next 5–10 years,
whole-genome sequencing may replace
conventional newborn screening in much
of the developedworld. Initially, only those
genes for which immediate diagnosis in
a newborn is of clear value for directing
medical management are likely to be eval-
uated, including the 20–30 genes
comprising current newborn screening
panels, with the rest of the sequence
archived for later use. The list of such
actionable Mendelian genetic disorders
will undoubtedly expand with time. The
availability of full genome sequences for
large fractions of the patient population,
together with implementation of a uniform
electronic medical record, should enable
an entirely new scale of genetic epidemio-
logic health outcomes research. Along
with these advances, issues of informed
consent and genetic privacy, as well as
ethical considerations related to prenatal
and preimplantation intervention, will
pose increasingly complex challenges.
The anticipated flood of sequencing
data, along with the development of new
computational and conceptual tools to
analyze it, are likely to yield profound
new insights into the pathogenesis of
human disease, the diagnosis of complex
genetic disorders, and the accurate
prediction of drug efficacy and toxicity,
leading to improved treatment selection.
The near future promises to be a very
exciting time for biomedical research,
perhaps finally providing the tools re-
quired to realize the promise of translating
basic scientific discovery into improved
outcomes for patients.
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